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Abstract
Background: Intra-articular injection of mesenchymal stem cells (MSCs) is efficacious in osteoarthritis therapy. A
direct comparison of the response of the synovial joint to intra-articular injection of autologous versus allogeneic
MSCs has not been performed. The objective of this study was to assess the clinical response to repeated intra-
articular injection of allogeneic versus autologous MSCs prepared in a way to minimize xeno-contaminants in a
large animal model.
Methods: Intra-articular injections of bone marrow-derived, culture-expanded MSCs to a forelimb
metacarpophalangeal joint were performed at week 0 and week 4 (six autologous; six autologous with
xeno-contamination; six allogeneic). In the week following each injection, clinical and synovial cytology
evaluations were performed.
Results: Following the first intra-articular injection, there were no differences in clinical parameters over
time. Following the second intra-articular injection, there was a significant adverse response of the joint
to allogeneic MSCs and autologous MSCs with xeno-contamination with elevated synovial total nucleated
cell counts. There was also significantly increased pain from joints injected with autologous MSCs with
xeno-contamination.
Conclusions: Repeated intra-articular injection of allogeneic MSCs results in an adverse clinical response,
suggesting there is immune recognition of allogeneic MSCs upon a second exposure.
Keywords: MSC, Bone marrow, Serum-free, Horse, Joint, Flare, Intra-articular, Fetal calf serum, Fetal bovine
serum, FBS
Background
The equine model is valuable for assessing stem cell
therapies for musculoskeletal injury due to similarities in
sport and age-related articular injuries that occur in
people [1] and for the clinical experience of stem cell
techniques in the horse for naturally occurring injury
over the past several years [2]. Experimentally and clinic-
ally, intra-articular injection of autologous mesenchymal
stem cells (MSCs) in the horse resulted in reduced pain
and slowed osteoarthritis progression in an articular car-
tilage repair model [3] and clinical equine patients [4].
Positive effects of MSCs on osteoarthritis in the horse
and other large animal models [5] have led to develop-
ment of clinical trials in people utilizing both autologous
and allogeneic MSCs for intra-articular injection [6–13].
Allogeneic MSCs would be advantageous to autolo-
gous MSCs for a number of reasons [14]. Since the first
report of allogeneic MSCs in a clinical patient in 2004,
allogeneic MSCs have been used in more registered clin-
ical trials in the United States and undergone more
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published scientific reports than the use of autologous
MSCs [15, 16]. In contrast, for intra-articular application
of MSCs in people, there have been more reports of
autologous MSC use [6–11] and only one report on
allogeneic MSCs [12]. To our knowledge, there have
been no reports directly comparing the clinical response
to intra-articular injection of autologous and allogeneic
MSCs other than those in the equine model, where a
lack of clinically relevant differences have been reported
[17, 18]. However, in each of these experimental reports,
moderate to marked adverse clinical reaction with pain
and joint effusion with cellular infiltrates were reported
after a single intra-articular injection of autologous or
allogeneic MSCs [17, 18]. Interestingly, when autologous
and allogeneic chondroprogenitor cells were compared
in the equine model there was reduced osteoarthritis
progression when autologous cells were used but not
allogeneic [19]. Because of the acute adverse reaction in
these reports, we pose that the safety of allogeneic MSCs
by intra-articular injection has not been fully investi-
gated. Additionally, there are no reports on the response
to repeated intra-articular injection of autologous or
allogeneic MSCs in any species.
Safety of allogeneic MSC therapy by many routes of
administration is relatively well-accepted. However, the
articular environment is unique and considered to be
particularly prone to immune reactions. First, the syn-
ovial joint is a confined space lined by synovial mem-
brane that provides a blood-joint barrier [20–22]. As a
result, large molecules such as proteins and cells do not
equilibrate from the joint to the systemic circulation as
rapidly as from most other tissues and organs. Second,
the synovial membrane is composed of two major cell
types: type A macrophage-like synoviocytes and type B
fibroblast-like synoviocytes. The presence of type A,
macrophage-like synoviocytes may lend the articular en-
vironment to enhanced immune responses and antigen
recognition compared to other tissues [22].
Fetal bovine serum (FBS) is well recognized as a major
safety concern prior to cell implantation in people be-
cause of development of antibodies to contaminating bo-
vine proteins with subsequent rejection of cellular
therapies [23–28]. Despite this, over half of reported
MSC clinical trials utilize FBS during culture of MSCs
[29]. This is because it is difficult to provide the
necessary growth factors, hormones, vitamins, binding
proteins, and other compounds that do not alter cellular
behavior without FBS [29–31]. The reports that
compared the articular reaction to autologous and allo-
geneic MSC injection in the equine model utilized FBS
throughout their cellular propagation up to the time of
intra-articular injection [17, 18].
We think the previously reported joint flare response to
both autologous and allogeneic MSCs by intra-articular
injection in the equine model could have been due to con-
taminating xeno-proteins [17, 18]. If this adverse response
was due to xeno-contaminants, differences in the articular
joint response to autologous versus allogeneic MSCs could
have been masked by the marked inflammatory reaction
to xenogeneic protein. Thus, our objectives were twofold.
First, we wanted to characterize the clinical joint response
to repeated intra-articular MSC injection with a method
to reduce the level of contaminating bovine proteins com-
pared to FBS-containing methods. Second and more im-
portantly, we wanted to characterize the clinical response
of the equine synovial joint to repeated intra-articular in-
jection of autologous and allogeneic MSCs, cultured in a
manner to reduce contaminating bovine proteins. For the
first objective, we demonstrated that intra-articular injec-
tion of autologous MSCs without efforts to minimize bo-
vine protein contamination resulted in markedly increased
adverse clinical reaction. For the second objective, when
there is a reduction in contaminating bovine proteins by
laboratory technique, the repeated intra-articular injection
of allogeneic MSCs resulted in increased adverse clinical
reaction compared to the injection of autologous MSCs,
supporting the notion that there is an adaptive immune
response of the synovial joint to intra-articular injection of
allogeneic MSCs.
Methods
This study was approved by the university’s Institutional
Animal Care and Use Committee (IACUC protocol num-
ber 2013-097). No animals were euthanized for this study.
Study design
There were three groups of horses that received intra-
articular injection of MSCs to a metacarpophalangeal
joint: autologous cells depleted of FBS (AUTO; n = 6),
allogeneic cells depleted of FBS (ALLO; n = 6), and
autologous cells not depleted of FBS (FBS; n = 6).
Mesenchymal stem cells from each AUTO horse were
injected to one ALLO horse so there were six AUTO to
ALLO pairs. The MSCs were prepared in vitro similar to
previous reports [17, 18, 32] with FBS in the media
throughout the culture period. However, for FBS deple-
tion in the AUTO and ALLO groups, FBS was removed
from culture medium in the final 48 hours of MSC cul-
ture prior to intra-articular injection. The contralateral
joint was injected with the same media used to suspend
MSCs, alone (CONT).
Horses did not receive nonsteroidal anti-inflammatory
medications and the limbs were not bandaged. Horses
were housed individually in box stalls the week following
intra-articular injection and serial clinical evaluations were
performed. During the 3 weeks prior to the second intra-
articular injection, horses were turned out to their normal
group housing (field setting). Four weeks after the initial
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intra-articular injection, a repeat injection was performed
and followed by the same post-injection evaluation.
Animals
Eighteen university-owned horses were used. All horses
were female of the Quarter Horse breed and the age me-
dian age was 11.5 years (range 3–17; Additional file 1:
Table S1). Within the ALLO group, one of the six mares
had experienced a pregnancy prior to the study. Prior to
inclusion in the study, horses were declared to be
healthy based upon physical examination and did not
have abnormalities related to the forelimb metacarpo-
phalangeal joints as determined by normal range of mo-
tion, lack of joint effusion, and lack of response to joint
flexion. Radiographic or other diagnostic imaging of the
joints was not performed. Each horse was randomly
assigned to a treatment group using an online program
(http://www.random.org/). The treated forelimb was also
randomly assigned by coin toss for each horse immedi-
ately prior to their initial intra-articular injection. The
contralateral forelimb was used for CONT injection.
MSC preparation
Bone marrow was collected from the sternum for the
isolation and expansion of MSCs from all six horses in
the AUTO and FBS groups as previously described [33].
Bone marrow was not collected from the six horses in
the ALLO group. In brief, after red blood cell lysis, bone
marrow samples were resuspended in their original vol-
ume and plated at 30 mL original marrow volume/
175 cm2 flask. At each passage MSCs were seeded at a
density of 10,000 MSCs/cm2. Once MSCs were ad-
equately expanded for all experiments and at approxi-
mately 60% of confluence in passage 3 or 4, the MSCs
intended for clinical injection in the AUTO and ALLO
groups underwent FBS depletion. The final 48-hour
treatment consisted of culture in complete medium sup-
plemented with 10% autologous serum with the addition
of ITS supplement (VWR, Radnor, PA, USA) (AUTO
and ALLO) or continued growth in complete media with
10% FBS (FBS). The addition of ITS was performed be-
cause in previous experiments in our laboratory (data
not shown) there was tremendous variability in MSC
growth and metabolism when grown in autologous
serum, which we presumed was due to differences in the
quality of autologous serum. When we added ITS in pilot
experiments to autologous serum supplemented MSCs, it
allowed continued growth and metabolism, resulting in ex-
pulsion of intracellular FBS. Adherent MSCs were rinsed
twice with 10 mL of Dulbecco’s phosphate-buffered saline
(DPBS) (Lonza, Walkersville, MD, USA) prior to the
medium exchange and medium was replaced again after
24 hours of culture. Forty-eight hours after FBS depletion,
adherent MSCs were collected by trypsinization (Corning,
Corning, NY, USA), rinsed by centrifugation and resuspen-
sion three times, and cryopreserved in 95% autologous
serum and 5% dimethyl sulfoxide (DMSO) at a concentra-
tion of 10 × 106 MSC per mL.
Assessment of FBS depletion
Concurrent with cellular preparation for clinical injec-
tion, separate MSCs in the AUTO and FBS groups were
used to assess FBS depletion. As previously described,
FBS was covalently labeled with fluorescein isothiocyan-
ate (FITC) [23]. The protein concentration used post
FITC labeling was similar to the original FBS protein
concentration and FITC-FBS was added to all complete
media at 10%. Media was exchanged for FITC-FBS-
containing media in two culture flasks (per MSC donor)
at a time point equivalent to 4 days prior to cryopreser-
vation (at approximately 20–30% confluence). After
2 days, one culture flask of the FITC-labeled MSCs had
medium exchanged with FBS-free complete medium
(supplemented with 10% autologous serum and ITS) as
described above for FBS depletion. The other FITC-FBS
flask was maintained in fresh FITC-FBS for the final
48 hours of culture. MSCs from both flasks were then
assessed for fluorescence intensity by flow cytometry
(FACSCalibur, Becton Dickinson Immunocytometry Sys-
tems, San Jose, CA, USA), as a measure of remaining
intra-cytoplasmic FITC-FBS. The population doubling
time was calculated (days * log(2))/(log final concentra-
tion – log initial concentration).
MSC characterization in vitro
Immunophenotyping and trilineage differentiation was
performed as previously described [33] on cells of the
same passage and prepared in the same manner as those
used for clinical injection. Briefly, dilutions of 1:100 for
CD44 (Clone CVS18; Abcam, Cambridge, MA, USA),
major histocompatibility complex class II (MHCII)
(Clone CVS20; Abcam), CD29 (Clone 4B4-RD1; Beckman
Coulter, Brea, CA, USA), 1:10 for CD45RB (Clone
DH16A; VMRD, Inc., Pullman, WA, USA), and 1:400 for
CD90 (Clone DH2A; VMRD, Inc.) were used. CD45RB
and CD90 were stained with 1:100 secondary antibody
(Jackson ImmunoResearch, West Grove, PA, USA). Im-
mediately prior to analysis all cells were labeled with 7-
AAD (Biolegend, San Diego, CA, USA) to assess viability.
For chondrogenic differentiation, MSCs were grown in
pellets of 500,000 cells for 21 days before being sec-
tioned and stained with toluidine blue (Sigma-Aldrich,
St. Louis, MO, USA). Cells were grown in Dulbecco’s
modified Eagle’s medium 4.5 g/l glucose supplemented
with 1% FBS, 2.5% HEPES buffer, 10,000 units/mL
penicillin, 10,000 μg/mL streptomycin, 25 μg/mL
amphotericin B, 0.2% transforming growth factor β3
(Life Technologies, Grand Island, NY, USA), 301.89 μg
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dexamethasone (Sigma-Aldrich), 50 μg/mL L-ascorbic
acid (Sigma-Aldrich), 40 μg/mL proline (Sigma-Aldrich)
and 1% ITS premix (VWR).
For osteogenic differentiation, MSCs were seeded to
10-cm plates at 1000 cells per cm2 grown for 21 days
with media exchanged three times weekly before staining
with 2% alizarin red (Sigma-Aldrich). Osteogenic media
contained Dulbecco’s modified Eagle’s medium F12 sup-
plemented with 10% FBS, 10,000 units/mL penicillin,
10,000 μg/mL streptomycin, 25 μg/mL amphotericin B,
10 μM/L beta-glycerophosphate (Sigma-Aldrich), 20nM/
L dexamethasone, and 50 μg/mL L-ascorbic acid.
For adipogenic plates, MSCs were seeded to 10-cm
plates at 1000 cells per cm2 and grown for 6 days before
fixing and staining with oil red O (Sigma-Aldrich).
Adipogenic plates were maintained in Dulbecco’s modi-
fied Eagle’s medium F12 (VWR) supplemented with 3%
FBS, 10,000 units/mL penicillin, 10,000 μg/mL strepto-
mycin, 25 μg/mL amphotericin b, 5% rabbit serum (Life
Technologies), 33 μM/L biotin (Sigma-Aldrich), 17 μM/
L pantothenate (Sigma-Aldrich), 1 μM/L insulin (Sigma-
Aldrich), 1 μM/L dexamethasone, 225 μL isobutyl-
methylxanthine (Sigma-Aldrich), 89 μL rosiglitazone
(Sigma-Aldrich). After 3 days, media was then ex-
changed without the addition of isobutylmethylxanthine
or rosiglitazone and maintained for another 3 days.
Intra-articular MSC injection
Horses were sedated with 0.4 mg/kg xylazine hydro-
chloride (Lloyd Inc., Shenandoah, IA, USA) (100 mg/
mL). The lateral aspect of each metacarpophalangeal
joint was aseptically prepared. Immediately prior to joint
injection, vials containing MSCs (AUTO, ALLO or FBS
previously frozen in 95% autologous serum and 5%
DMSO) or media alone (the same media composition
used for MSCs) were thawed in a 37 °C water bath. A
20-gauge, 1-inch needle was inserted into the joint distal
to the lateral collateral sesamoidean ligament and 2 mL
of synovial fluid was collected and transferred to tubes
containing EDTA for cytological analysis. Following
synovial fluid collection, MSC or CONT injection was
performed as appropriate for each joint. Control joints
were injected with 1 mL of 95% autologous serum and
5% DMSO and MSC joints were injected with approxi-
mately 10 million MSCs suspended in 1 mL of 95% au-
tologous serum and 5% DMSO.
Serial evaluations - synovial cytology
On the day of injection (day 0 and day 29) and on days
1, 2, 3, and 7 (and 30, 31, 32, and 36) after injection,
cytological evaluation of synovial fluid was performed on
all cell-injected and control joints. Synovial fluid cyto-
logical evaluation was performed in control joints on
days 0 and 1, and days 29 and 30. Collection of synovial
fluid was performed as described above for the MSC in-
jections. Evaluations included total protein concentra-
tion via refractometry, total nucleated cell count, and
total nucleated cell differential, and a cytological evalu-
ation by a board-certified veterinary clinical pathologist.
Serial evaluations - clinical evaluation
Horses were monitored by routine physical examination
and assessed for lameness at a walk every 12 hours for
the week following each intra-articular injection. If any
horse had lameness visible at a walk for ≥ 24 hours, res-
cue analgesia was administered (4.4 mg/kg phenylbuta-
zone, intravenously (IV) every 24 hours) until lameness
was no longer visible at a walk. Assessment of lameness
was done with an objective inertial sensor system
(Lameness Locator®) as previously described [34, 35] on
the same days and immediately prior to synovial fluid
collection from injected joints.
Statistical analysis
Data were imported into a commercial statistical soft-
ware program (SAS, version 9.4; SAS Institute Inc., Cary,
NC, USA) for analysis. Repeated measures analysis of
variance (ANOVA) was used to compare temporal
changes in the cytologic and clinical outcome variables
for each pair of treatment groups, with horse considered
a random effect. These analyses were performed using
PROC MIXED, and an autoregressive correlation struc-
ture was specified. Treatment group, time point, and
their interaction were included as factors in the
ANOVA. The Wilcoxon rank-sum test was used to com-
pare population doubling time between the autologous
serum-treated MSCs and the FBS-treated MSCs. For all
analyses, p values < 0.05 were considered significant.
Results
Bone marrow-derived MSCs were successfully isolated
and expanded from all horses in the AUTO and FBS
groups. All joint injections and follow-up procedures
went well, and no horse had any adverse event that re-
quired cessation of the study or unplanned procedures
or treatments. No horses had abnormalities identified on
twice daily physical examinations in the week following
each intra-articular injection. Although two horses had
lameness at a walk 8 hours after intra-articular injec-
tion (one after the initial injection in the control
limb of the FBS group and one after the repeated in-
jection in the cell-treated limb of the ALLO group),
this was resolved by 24 hours and therefore no
horses required rescue analgesic medication. The
median age was 11.5 years (range 3–17; Additional
file 1: Table S1) and all were female.
The population doubling time for MSCs prepared for
clinical injection was not different between the autologous
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serum-prepared MSCs (2.5, 2.3–4.1; median, IQR) and the
FBS-prepared MSCs (2.4, 1.8–3.2; median, IQR). Cell via-
bility was 70%; ±15% (mean; standard deviation)
after the initial injection and 85%; ±7% after the sec-
ond injection.
FBS depletion
All MSC cultures grown with FITC-FBS were visibly
fluorescent under UV light. After removal of FITC-FBS
complete media, intra-cytoplasmic fluorescence could be
detected under UV light (Additional file 2: Figure S1A).
After 48 hours of culture in autologous supplemented
complete media there was little remaining intra-
cytoplasmic fluorescence for MSCs from all horses
(Additional file 2: Figure S1B). Flow cytometry revealed
that the mean fluorescence intensity (MFI) of cell
cultures without FBS was reduced by a greater than 95%
compared to that of cells maintained in FITC-FBS
(Additional file 2: Figure S1C). The population doubling
time during the FBS depletion period was not different
(p = 0.15) between the autologous serum-treated MSCs
(2.9, 1.5–6.0; median, IQR) and the FITC-FBS-treated
MSCs (2.1, 1.5–4.0; median, IQR).
MSC characterization in vitro
All MSCs were positive for CD90 and CD29, and nega-
tive for CD45; three horses were positive for CD44 and
the remaining nine were negative; and two horses were
positive for MHCII and the remaining ten were negative
(Table 1; Additional file 3: Figure S2). All MSCs were
positive for trilineage differentiation after osteogenic,
chondrogenic, and adipogenic differentiation (Additional
file 4: Figure S3).
Synovial cytology
Following the first joint injection, the change in total nu-
cleated cell count (TNCC) over time was not signifi-
cantly different between either the AUTO and FBS
groups or the AUTO and ALLO groups. Following the
second joint injection 4 weeks later, there was a signifi-
cant difference in the TNCC over time between the
AUTO and FBS groups (p = 0.03; FBS was higher) and
the AUTO and ALLO groups (p = 0.009; ALLO was
higher). Specifically, there was a significant group effect
at day 30 for the AUTO and FBS groups (p = 0.0007;
FBS was higher) and the AUTO and ALLO groups (p =
0.0009; ALLO was higher). Other cytology parameters
did not differ significantly over time between groups
after the first or second intra-injection (Fig. 1). The
modest changes in percentage of neutrophils and total
protein were similar to those from control injected ar-
ticular joints, which did not vary with time (Additional
file 5: Figure S4).
There were MSCs from two horses that expressed
MHCII molecules: one was in the FBS group and the
horse received its own MSCs and the other was in the
ALLO group. Horse 14 in the ALLO group received
MHCII-positive cells from horse 2. The day after the ini-
tial cell injection, horse 14’s TNCC (14,841 cells/μL;
ALLO median of 11,025 cells/μL), TP (0.1 g/dL; ALLO
median of 2.2 g/dL) and percentage of neutrophils (54%;
ALLO median of 55%) were similar to the ALLO group
medians. The day after the second intra-articular cell in-
jection, horse 14’s TNCC (19,674 cells/μL; ALLO me-
dian of 19,234 cells/μL) and TP (2.4 g/dL; ALLO median
of 2.55 g/dL) were similar to the group median. However
the percentage of neutrophils was the highest of the
group at 75% (ALLO group median of 52%).
One mare within the ALLO group, horse 17, had ex-
perienced a pregnancy prior to the study. The day after
the initial cell injection, horse 17’s TNCC (18,360 cells/
μL; ALLO median of 11,025 cells/μL) was slightly higher
than the group median. The day after the second cell in-
jection, horse 17’s TNCC (17,472 cells/μL; ALLO me-
dian of 19,234 cells/μL) was slightly lower than the
group median.
Clinical evaluation
Lameness was evident at a walk in two horses the day of
intra-articular MSC injection, but was resolved within
24 hours. Therefore no horses required rescue analgesia.
After the first injection, there was a marginal differ-
ence in the Lameness Locator® evaluation over time be-
tween the AUTO and FBS groups (p = 0.06) but not
between the AUTO and ALLO groups (p = 0.2). After
the second injection, there was a significant difference
between the AUTO and FBS groups (p = 0.046; FBS had
increased lameness) and a marginal difference between
Table 1 Cell surface markers of MSCs
Horse # Group MHCII CD44 CD29 CD45 CD90
1 FBS + - + - +
2 AUTO/ALLO + - + - +
3 FBS - + + - +
4 AUTO/ALLO - - + - +
5 AUTO/ALLO - - + - +
6 FBS - - + - +
7 FBS - - + - +
8 AUTO./ALLO - - + - +
9 FBS - - + - +
10 AUTO/ALLO - + + - +
11 FBS - - + - +
12 AUTO/ALLO - + + - +
MSCs mesenchymal stem cells, MHCII major histocompatibility complex class II,
FBS autologous cells not depleted of fetal bovine serum (FBS), AUTO
autologous cells depleted of FBS, ALLO allogeneic cells depleted of FBS
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Fig. 1 Synovial fluid cytology box plots of total nucleated cell count (TNCC), percentage of neutrophils (PMN), total protein concentration (TP),
percentage of lymphocytes and percentage of monocytes. Repeated measures analysis of variance (ANOVA) was used to compare temporal
changes in the cytologic outcome variables for each pair of treatment groups (AUTO to FBS and AUTO to ALLO), with horse considered a
random effect. These analyses were performed using PROC MIXED, and an autoregressive correlation structure was specified. Treatment group
(AUTO, ALLO or FBS), time point, and their interaction were included as factors in the ANOVA. Following the first intra-articular MSC injection, the
change in total nucleated cell count (TNCC) over time was not significantly different between either the AUTO and FBS groups or the AUTO and
ALLO groups. Following the second joint injection 4 weeks later, there was a significant difference in the TNCC over time between the AUTO and
FBS groups (p = 0.03; FBS was higher) and the AUTO and ALLO groups (p = 0.009; ALLO was higher). Specifically, there was a treatment effect at
day 30 for the AUTO and FBS groups (p = 0.0007; FBS was higher) and the AUTO and ALLO groups (p = 0.0009; ALLO was higher). Other cytology
parameters did not vary over time for either group after either injection. FBS autologous cells not depleted of fetal bovine serum
(FBS), AUTO autologous cells depleted of FBS, ALLO allogeneic cells
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the AUTO and ALLO groups (p = 0.09; ALLO had in-
creased lameness). There was a significant group effect
at day 30 between the AUTO and FBS groups (p =
0.0006; FBS had increased lameness) (Fig. 2).
Discussion
In this manuscript, there are three main findings. First,
laboratory technique to remove xeno-contaminants aris-
ing from fetal bovine serum prior to injection of MSCs
has a profound effect on the clinical reaction of the syn-
ovial joint after intra-articular MSC injection. Using
fluorescent microscopy and flow cytometry we demon-
strated a greater than 95% reduction in intracellular
FITC-FBS after a 48-hour FBS depletion culture period.
Xeno-contamination of MSCs when FBS depletion was
not performed resulted in marked adverse clinical reac-
tion to a single and repeated intra-articular injection of
autologous MSCs compared to autologous MSCs that
were FBS-depleted. Second, in strong contrast to previ-
ous reports [17, 18] a single intra-articular injection of
autologous MSCs did not result in an adverse clinical re-
action and there were no increases in TNCC, joint effu-
sion or pain [17, 18]. The third and foremost finding
was that repeated intra-articular injection of allogeneic
MSCs resulted in adverse clinical reaction after a second
injection, 4 weeks later. The increased adverse reaction
was characterized by a trend of increased lameness and
significantly increased synovial cellular infiltrates com-
pared to autologous MSCs by repeated intra-articular in-
jection. Given the increased adverse clinical reaction
after the second intra-articular injection of allogeneic
MSCs, it is likely that the reaction is due to adaptive im-
mune activation by allogeneic MSCs but not autologous
MSCs.
Control joints injected with media alone (95% au-
tologous serum and 5% DMSO that had been thawed
immediately prior to injection) were used to assess
for a response to synoviocentesis and media itself. In
cell-injected joints, there were mild increases in the
percentage of neutrophils and total protein after the
initial MSC injection in all three groups. These values
were further increased after the second injection,
again for all three groups. Because similar changes
were seen in the control injected joints, this is simply
a response of the synovial joint to synoviocentesis
and to the control media itself. The elevations in
neutrophils and total protein and lack of elevation in
TNCC from our control injected joints were less than
that reported after intra-articular saline injection,
which causes a mild and transient synovitis [36].
Immune responses to allograft can occur via several
pathways involving both innate and adaptive immunity.
Although the immune privilege and immune modulatory
activity of allogeneic MSCs in vitro is fairly well under-
stood and frequently cited, allogeneic MSCs are now be-
ing considered immune-evasive in vivo rather than truly
immune privileged [16]. This is because of the reduced
long-term persistence of allogeneic MSCs [37–42], in-
creased allo-antibody production [43, 44], increased cel-
lular infiltrates [37–39, 45], and complete immune
responses (cellular and humoral) [46, 47] that occur after
allogenic MSC administration compared to autologous.
Thus, immune responses to allogeneic MSCs secondary
to their immunogenicity could negatively impact cellular
longevity and efficacy [16, 48, 49].
The expression of MHCII by equine MSCs has been
reported to be variable [50] despite maintaining the ex-
pected immunophenotype for MSCs and expected ability
Fig. 2 Box plot of the change of Lameness Locator® scores compared to the baseline examination at day 0 and 29. Repeated measures analysis
of variance (ANOVA) was used to compare temporal changes in the change of lameness from baseline for each pair of treatment groups (AUTO
to FBS and AUTO to ALLO), with horse considered a random effect. These analyses were performed using PROC MIXED, and an autoregressive
correlation structure was specified. Treatment group (AUTO, ALLO or FBS), time point, and their interaction were included as factors in the
ANOVA. After the first injection, there was a marginal difference in the Lameness Locator® evaluation over time between the AUTO and FBS
groups (p = 0.06; FBS had increased lameness) but not between the AUTO and ALLO groups (p = 0.2). After the second injection, there were
significant differences between the AUTO and FBS groups (p = 0.046; FBS had increased lameness) and a marginal difference between the AUTO
and ALLO groups (p = 0.09; ALLO had increased lameness). There was a significant treatment effect at day 30 between the AUTO and FBS groups
(p = 0.0006; FBS had increased lameness). FBS autologous cells not depleted of fetal bovine serum (FBS), AUTO autologous cells depleted of FBS,
ALLO allogeneic cells depleted of FBS
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to undergo trilineage differentiation. One horse in this
study within the ALLO group received MSCs that were
MHCII positive. This did not influence the adverse joint
reaction and the values of TNCC and TP from the indi-
vidual horse were similar to the ALLO group medians,
which indicate that T cell responses are not responsible
for the adverse clinical response or that the AUTO
ALLO paired was MHC compatible. Thus it is more
likely that MHCI or other cell surface molecules are re-
sponsible for the apparent immunogenicity of allogeneic
MSCs that we demonstrate.
Pregnancy can prime a mother against the foreign
MHC haplotype(s) of her offspring’s father, and all ani-
mals in this study were female [51]. Within the allogen-
eic group, only one horse had experienced a pregnancy.
The synovial TNCCs the day following the initial and
primed injections from this horse were similar to the
ALLO group medians and not different to each other,
suggesting that the allogeneic MSCs she received were
either of a different MHC haplotype than the sire of her
foal, or that she did not mount a primed immune re-
sponse for another reason, including the possibility that
she might have shared the same MHC haplotype as the
sire of her foal. Nevertheless, it is important to recognize
the importance of the chance for priming against MHC
molecules in females that have been pregnant and will
receive allogeneic cells.
Despite recognition of potential problems associated
with xeno-contaminants in MSCs [23, 29–31, 52] FBS
was used throughout the MSC isolation and propaga-
tion in each of the previously reported experimental
studies evaluating intra-articular MSC injection in the
equine model [17, 18, 53]. In the report herein, FBS
was utilized until the final 48 hours of the culture
period where FBS was replaced with autologous
serum to minimize the immunogenicity of xeno-
contamination of MSCs. This FBS depletion protocol
resulted in a greater than 95% reduction in the
amount of contaminating intracellular bovine proteins
and a concomitant reduction in adverse inflammatory
reaction to autologous MSCs following repeated intra-
articular injection.
Since there was incomplete removal of FBS, differ-
ences in MSC growth rate or metabolism could have led
to small individual differences in the clearance of intra-
cellular FBS during the 48-hour FBS depletion period.
Given the marked response of the synovial joint to FBS-
contaminated MSCs, it is possible the minor differences
in the level of xeno-contaminants could cause major
changes in recipient immune reaction. The use of au-
tologous and allogenic matched pairs controlled for this
possibility because each group (AUTO and ALLO)
would have received the same amount of persisting
xeno-contaminant.
We expected there would be a marked adverse re-
sponse of the joint after intra-articular injection of MSCs
prepared with xeno-contamination (FBS group), similar
to that reported previously [17, 18]. A surprising finding
was that even from this group, the post-injection TNCC
after the initial injection was very low (approximately 1/
3 to 1/5) compared to previous reports. This was despite
intra-articular injection with a similar number of autolo-
gous bone marrow-derived MSCs [17, 18]. Reduced ad-
verse reaction to the initial MSC injection contaminated
with FBS reported herein could be due to differences in
laboratory preparation techniques [54]. The MSCs of
this report were cryopreserved until immediately prior
to intra-articular injection, which is in contrast to the
prior reports where fresh MSCs were utilized [17, 18].
Interestingly, our synovial TNCC was comparable to
that reported by Williams et al., who tested cryopre-
served allogeneic cord blood-derived MSCs for intra-
articular injection in the equine model [53]. It is possible
that cryopreservation somehow selects for or signals
MSCs to be “better” [33, 55]. Interestingly, cryopreserva-
tion may also impair the immunomodulatory properties
of MSCs [56]. Certainly in our experiment after the ini-
tial injection, if cryopreservation had an effect, it ap-
peared to be one of improved immunomodulatory
properties because of lack of adverse clinical reaction in
all groups after the initial MSC injection.
In addition to a possible effect on the cells by the
cryopreservation and thawing process, cryopreservation
media components themselves (DMSO or serum) may
also be protective against an adverse inflammatory reac-
tion in the synovial environment as both DMSO and
serum are known to be anti-inflammatory [57, 58]. How-
ever, all injected joints received the same amount of
DMSO and autologous serum, so if there was an effect,
it would have reduced the adverse clinical reaction in all
groups. Certainly, the anti-inflammatory effects of media
were not enough to abolish the increased adverse clinical
reaction in the ALLO and FBS groups. Finally, the
amount of DMSO was 50 μL per joint, which is a very
small dose for an equine metacarpophalangeal joint that
has a joint volume of approximately 12.5 mL [59].
Cell viability at the time of intra-articular injection
could affect the host response. After the initial injec-
tions, cell viabilities were lower than expected (70%)
based on previous experience [60]. This is because the
animal site was distant to the laboratory causing a sig-
nificant lag between thawing and testing of cell viability.
At the second intra-articular injection extra effort was
made to transport the tubes and test the viability as
quickly as possible. Unfortunately, there was still a time
delay of 1–2 hours and viability (85%) remained lower
than expected based on previous experience [60]. Thus,
the viabilities reported herein do not reflect MSC
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viability at the time of injection or even 1–2 hours
following injection in vivo. This is because of the very
different environment of the synovial joint as compared
to an undiluted laboratory vial. Thus no attempts were
made to compare the adverse clinical reaction to post-
thaw MSC viability.
Another MSC factor that could affect the synovial re-
sponse to MSCs is the metabolic activity of the cells at
the time of intra-articular injection. Population doubling
times were calculated as a measure of metabolic rate
and there were no differences between the groups.
Therefore, differences in MSC growth should have af-
fected all three groups equally. However, if there were
differences in the metabolic rate of injected MSCs within
each group, we expected that injection of MSCs contain-
ing FBS contamination would have the greatest effect on
clinical response. This is because very metabolically ac-
tive MSCs would release FBS to the synovial environ-
ment at a faster rate than a senescent cell. We found the
widest variability in adverse clinical reaction in the FBS
group after the second intra-articular injection, and the
two horses with the lowest population doubling times
(most metabolically active) had the highest total nucle-
ated cell counts in that group. This is indirect evidence
that differences in the metabolic rate of MSCs resulted
in variability in the exposure of the intra-articular
environment to xeno-antigens and the resultant host
response. Certainly, future studies should report the
growth rate of MSCs immediately prior to treatment
injection as it may affect host response and cellular
efficacy.
A limitation of this study is that all joints were normal
and it is possible that there would be a different re-
sponse of the inflamed or osteoarthritic synovial joint to
allogeneic MSCs or MSCs contaminated with FBS.
Given the results of our study, further study to deter-
mine the response of the abnormal joint to allogeneic
MSCs should be performed. This is especially important
because it has been previously shown that inflammatory
stimulation in vitro can induce MSCs to express MHCII,
which would enhance the immunogenicity of allogeneic
MSCs [50].
A final limitation of this study is that the MHC haplo-
type and whether AUTO and ALLO pairs were MHC-
matched or mismatched is unknown. The study reported
here underpins the importance of fully understanding
the immunogenicity of allogeneic MSCs intended to be
used for intra-articular injection.
Conclusions
The synovial joint is a unique structure with a distinct
blood-joint barrier and different immune makeup of its
synovial lining. Understanding the clinical response of
the synovial joint to intra-articular injection of allogeneic
MSCs as compared to autologous MSCs is critical prior
to use of allogeneic MSCs in clinical patients by intra-
articular injection. Herein, we have shown there is
minimal reaction to a single or repeated intra-articular
injection of autologous MSCs when cells have been FBS
depleted, but not allogeneic MSCs, which is in direct
contrast to the previous reports in the equine model of a
strong adverse reaction after a single injection of autolo-
gous or allogeneic MSCs [17, 18]. Our concurrent test-
ing of autologous MSCs with xeno-contaminants from
the culture period demonstrate the cause of previously
reported profound adverse clinical reaction after autolo-
gous and allogeneic MSC intra-articular injection to
be intra-cellular xeno-contamination of injected MSCs.
The adverse clinical response of increased cellular infil-
trate in synovial joints injected with allogeneic MSCs and
increased pain and cellular infiltrate in synovial joints
injected with MSCs not depleted of FBS is clinically rele-
vant to patient morbidity and may also be relevant to
MSC persistence. This is because the cellular infiltrates
may indicate an adaptive immune response to the injected
MSCs, which may target MSCs for destruction.
Additional files
Additional file 1: Table S1. Horse number, age in years and group
assignments (DOCX 20 kb)
Additional file 2: Figure S1. FITC-labeled FBS depletion from MSCs
(no counterstain, red color is due to background transmitted light
resulting in autofluorescence). (A) MSCs prior to the FBS depletion period
of 48 hours and (B) and after the FBS depletion period of 48 hours. (C)
Histograms of MSCs from each horse in the FBS (top panels) and AUTO
groups (bottom panels) after 48 hours of FBS depletion in autologous
serum-supplemented culture medium (blue histogram) compared to
continued culture in FITC-FBS (green histogram). The gray histogram
represents cells not incubated with FITC-labeled FBS. All histograms
represent 2000–20,000 cells. (JPG 1595 kb)
Additional file 3: Figure S2. Histogram of MHC Class II expression of
MSCs from a (A) representative horse that was negative (horse 10) and
(B) horse 2 used for intra-articular injection to the MSC donor (AUTO) and
to an allogeneic recipient (horse 14; ALLO). All histograms represent
9000–11,000 cells. (JPG 138 kb)
Additional file 4: Figure S3. Trilineage differentiation of MSCs from a
single horse that represents the average result after (A) adipogenic (oil
red O), (B) osteogenic (alizarin red) and (C) chondrogenic (toluidine blue)
differentiation and the negative controls for (D) adipogenic and (E)
osteogenic differentiation. Cells from all horses successfully underwent
trilineage differentiation. Scale bars represent A, C, and D 100 um and B
and E 500 um. (JPG 657 kb)
Additional file 5: Figure S4. Synovial fluid cytology box plots of total
nucleated cell count (TNCC), percentage of neutrophils (PMN), and total
protein concentration (TP) for synovial joints injected with control media
only (95% autologous serum, 5% DMSO and no MSCs). Repeated
measures analysis of variance (ANOVA) was used to compare temporal
changes in the cytologic outcome variables for each pair of treatment
groups (AUTO to FBS and AUTO to ALLO), with horse considered a
random effect. These analyses were performed using PROC MIXED, and
an autoregressive correlation structure was specified. Treatment group
(AUTO, ALLO or FBS), time point, and their interaction were included as
factors in the ANOVA. There were no significant differences over time
between the groups. (JPG 491 kb)
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